文献速递临床试验与 GCP真实世界研究与卫生经济

预防性水化保护高对比剂肾病风险患者肾功能免受血管内碘对比剂影响(AMACING):一项前瞻性、随机、3期、对照、开放标签、非劣效性试验

Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
PubMed 文献 · Lancet · 2017-02-21

AMACING试验纳入660例eGFR 30-59 mL/min/1.73m²且接受择期碘对比剂操作的高危患者,随机接受静脉0.9% NaCl水化或无预防。对比剂肾病发生率无预防组2.6%(8/307)vs 水化组2.7%(8/296),绝对差-0.10%(单侧95%CI -2.25至2.06;单侧p=0.4710),无预防非劣效且节省费用;水化组5.5%(18/328)出现水化相关并发症。

要点

  • 在高危患者中,无预防组对比剂肾病发生率2.6% vs 水化组2.7%,绝对差-0.10%(单侧95%CI -2.25至2.06),符合非劣效。
  • 无预防相对于静脉水化可节省费用。
  • 水化组5.5%(18/328)发生与水化相关的并发症。

核心结论

  • 依据现行临床实践指南,在预防对比剂肾病方面,无预防措施不劣于静脉水化且节省费用。

研究设计与样本

  • AMACING为前瞻性、随机、3期、平行组、开放标签、非劣效性试验,在荷兰马斯特里赫特大学医学中心纳入18岁及以上、eGFR 30-59 mL/min/1.73m²、接受择期碘对比剂操作的高危患者。
  • 2014年6月17日至2016年7月17日,660例连续患者按1:1随机分配至无预防组(n=332)或静脉水化组(n=328),随机化按预设危险因素分层。
  • 排除eGFR低于30 mL/min/1.73m²、既往透析或未转诊静脉水化的患者;非劣效界值设为2.1%;主要结局为对比剂肾病发生率及无预防相对于静脉水化的成本效果。

主要发现

  • 对比剂肾病在无预防组307例中发生8例(2.6%),水化组296例中发生8例(2.7%)。
  • 绝对差(无预防 vs 水化)为-0.10%(单侧95%CI -2.25至2.06;单侧p=0.4710)。
  • 无预防相对于水化可节省费用;35天内无血液透析或相关死亡发生。
  • 水化组328例中18例(5.5%)发生与水化相关的并发症。

关键数值与推荐

  • 对比剂肾病定义为对比剂暴露后2-6天内血清肌酐较基线升高超过25%或44 μmol/L。
  • 非劣效界值设定为2.1%。

临床怎么用

  • 作者结论认为,根据现行临床实践指南,在预防对比剂肾病方面无预防措施不劣于静脉水化且节省费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous saline is recommended in clinical practice guidelines as the cornerstone for preventing contrast-induced nephropathy in patients with compromised renal function. However, clinical-effectiveness and cost-effectiveness of this prophylactic hydration treatment in protecting renal function has not been adequately studied in the population targeted by the guidelines, against a group receiving no prophylaxis. This was the aim of the AMACING trial. METHODS: AMACING is a prospective, randomised, phase 3, parallel-group, open-label, non-inferiority trial of patients at risk of contrast-induced nephropathy according to current guidelines. High-risk patients (with an estimated glomerular filtration rate [eGFR] of 30-59 mL per min/1·73 m2) aged 18 years and older, undergoing an elective procedure requiring iodinated contrast material administration at Maastricht University Medical Centre, the Netherlands, were randomly assigned (1:1) to receive intravenous 0·9% NaCl or no prophylaxis. We excluded patients with eGFR lower than 30 mL per min/1·73 m2, previous dialysis, or no referral for intravenous hydration. Randomisation was stratified by predefined risk factors. The primary outcome was incidence of contrast-induced nephropathy, defined as an increase in serum creatinine from baseline of more than 25% or 44 μmol/L within 2-6 days of contrast exposure, and cost-effectiveness of no prophylaxis compared with intravenous hydration in the prevention of contrast-induced nephropathy. We measured serum creatinine immediately before, 2-6 days, and 26-35 days after contrast-material exposure. Laboratory personnel were masked to treatment allocation. Adverse events and use of resources were systematically recorded. The non-inferiority margin was set at 2·1%. Both intention-to-treat and per-protocol analyses were done. This trial is registered with ClinicalTrials.gov, number NCT02106234. FINDINGS: Between June 17, 2014, and July 17, 2016, 660 consecutive patients were randomly assigned to receive no prophylaxis (n=332) or intravenous hydration (n=328). 2-6 day serum creatinine was available for 307 (92%) of 332 patients in the no prophylaxis group and 296 (90%) of 328 patients in the intravenous hydration group. Contrast-induced nephropathy was recorded in eight (2·6%) of 307 non-hydrated patients and in eight (2·7%) of 296 hydrated patients. The absolute difference (no hydration vs hydration) was -0·10% (one-sided 95% CI -2·25 to 2·06; one-tailed p=0·4710). No hydration was cost-saving relative to hydration. No haemodialysis or related deaths occurred within 35 days. 18 (5·5%) of 328 patients had complications associated with intravenous hydration. INTERPRETATION: We found no prophylaxis to be non-inferior and cost-saving in preventing contrast-induced nephropathy compared with intravenous hydration according to current clinical practice guidelines. FUNDING: Stichting de Weijerhorst.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017. PMID: 28233565. doi:10.1016/S0140-6736(17)30057-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。